Athol U Wells

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8190501/publications.pdf

Version: 2024-02-01

		1238	1505
447	54,840	110	219
papers	citations	h-index	g-index

454	454	454	26120
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 788-824.	5.6	6,033
2	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	5.6	3,134
3	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	5.6	2,678
4	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	5.6	1,521
5	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2019, 381, 1718-1727.	27.0	1,338
6	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	5.6	1,006
7	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 636-643.	5.6	996
8	Interstitial Lung Disease in Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1248-1254.	5.6	930
9	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. Chest, 2020, 158, 106-116.	0.8	832
10	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	6.7	803
11	Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Medicine,the, 2020, 8, 807-815.	10.7	802
12	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	30.5	786
13	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	10.7	739
14	Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1581-1586.	5.6	736
15	Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nature Genetics, 2013, 45, 613-620.	21.4	667
16	A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis and Rheumatism, 2006, 54, 3962-3970.	6.7	632
17	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 962-969.	5.6	571
18	Fibrotic Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 531-537.	5.6	544

#	Article	IF	Citations
19	Pulmonary sarcoidosis. Lancet Respiratory Medicine,the, 2018, 6, 389-402.	10.7	544
20	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	2.8	541
21	Idiopathic Nonspecific Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1338-1347.	5.6	528
22	Pulmonary Hypertension in Chronic Lung Diseases. Journal of the American College of Cardiology, 2013, 62, D109-D116.	2.8	518
23	The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 906-913.	5.6	453
24	Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. Annals of Internal Medicine, 2013, 158, 641.	3.9	437
25	Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1382-1389.	5.6	390
26	Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180076.	7.1	370
27	A CT Sign of Chronic Pulmonary Arterial Hypertension: The Ratio of Main Pulmonary Artery to Aortic Diameter. Journal of Thoracic Imaging, 1999, 14, 270-278.	1.5	362
28	Prediction of Pulmonary Complications and Longâ€Term Survival in Systemic Sclerosis. Arthritis and Rheumatology, 2014, 66, 1625-1635.	5.6	354
29	CT Features of Lung Disease in Patients with Systemic Sclerosis: Comparison with Idiopathic Pulmonary Fibrosis and Nonspecific Interstitial Pneumonia. Radiology, 2004, 232, 560-567.	7.3	338
30	Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respiratory Medicine,the, 2016, 4, 557-565.	10.7	337
31	Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. European Respiratory Journal, 2012, 40, 377-385.	6.7	335
32	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€"subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine,the, 2020, 8, 453-460.	10.7	331
33	Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. Respiration, 2016, 91, 215-227.	2.6	306
34	Nonspecific Interstitial Pneumonia and Usual Interstitial Pneumonia: Comparative Appearances at and Diagnostic Accuracy of Thin-Section CT. Radiology, 2001, 221, 600-605.	7.3	305
35	Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 745-752.	5.6	292
36	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	10.7	279

#	Article	IF	Citations
37	Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration, 2018, 95, 188-200.	2.6	273
38	The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 19-27.	0.2	273
39	The Relationship between Individual Histologic Features and Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 173-177.	5.6	262
40	Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax, 2016, 71, 45-51.	5.6	256
41	Six-Minute Walk, Maximal Exercise Tests. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1150-1157.	5.6	253
42	The pathogenesis of pulmonary fibrosis: a moving target. European Respiratory Journal, 2013, 41, 1207-1218.	6.7	252
43	Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respiratory Medicine,the, 2015, 3, 462-472.	10.7	252
44	ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.	6.7	248
45	Shortâ€Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 1670-1678.	5.6	247
46	Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1054-1060.	5.6	241
47	Nonspecific Interstitial Pneumonia: Variable Appearance at High-Resolution Chest CT. Radiology, 2000, 217, 701-705.	7.3	232
48	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax, 2007, 62, 248-252.	5.6	227
49	Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 435-446.	2.0	226
50	What's in a name? That which we call IPF, by any other name would act the same. European Respiratory Journal, 2018, 51, 1800692.	6.7	226
51	Rituximab in severe, treatmentâ€refractory interstitial lung disease. Respirology, 2014, 19, 353-359.	2.3	217
52	Prognostic Implications of Histologic Patterns in Multiple Surgical Lung Biopsies From Patients With Idiopathic Interstitial Pneumonias. Chest, 2004, 125, 522-526.	0.8	214
53	Follicular Bronchiolitis: Thin-Section CT and Histologic Findings. Radiology, 1999, 212, 637-642.	7.3	212
54	Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. European Respiratory Journal, 2017, 49, 1601011.	6.7	211

#	Article	IF	Citations
55	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	27.0	207
56	Acute Respiratory Distress Syndrome: CT Abnormalities at Long-term Follow-up. Radiology, 1999, 210, 29-35.	7.3	205
57	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	10.7	200
58	Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax, 2013, 68, 436-441.	5.6	193
59	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	10.7	190
60	Nonspecific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis: Changes in Pattern and Distribution of Disease over Time. Radiology, 2008, 247, 251-259.	7.3	186
61	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	10.7	185
62	Organizing Pneumonia: Perilobular Pattern at Thin-Section CT. Radiology, 2004, 232, 757-761.	7.3	182
63	The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax, 2012, 67, 804-810.	5.6	180
64	An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respiratory Medicine,the, 2014, 2, 123-130.	10.7	178
65	Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 208-217.	5.6	177
66	Detection of Pulmonary Hypertension with Multidetector CT and Echocardiography Alone and in Combination. Radiology, 2010, 254, 609-616.	7.3	176
67	Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax, 2014, 69, 216-222.	5.6	176
68	Interstitial Vascularity in Fibrosing Alveolitis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 438-443.	5.6	172
69	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	5.6	171
70	Hostâ€“Microbial Interactions in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1640-1650.	5.6	169
71	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	5.6	166
72	Lung Morphology in the Elderly: Comparative CT Study of Subjects over 75 Years Old versus Those under 55 Years Old. Radiology, 2009, 251, 566-573.	7.3	165

#	Article	IF	Citations
73	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 277-284.	10.7	162
74	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 190-194.	5.6	161
75	Interstitial lung disease in connective tissue diseaseâ€"mechanisms and management. Nature Reviews Rheumatology, 2014, 10, 728-739.	8.0	160
76	Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC: Cardiovascular Imaging, 2017, 10, 1437-1447.	5.3	160
77	Automated Quantitative Computed Tomography Versus Visual Computed Tomography Scoring in Idiopathic Pulmonary Fibrosis. Journal of Thoracic Imaging, 2016, 31, 304-311.	1.5	158
78	Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. European Radiology, 2012, 22, 1672-1679.	4.5	157
79	Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respiratory Research, 2017, 18, 29.	3.6	156
80	Bronchoalveolar lavage cellular profiles in patients with systemic sclerosisâ€"associated interstitial lung disease are not predictive of disease progression. Arthritis and Rheumatism, 2007, 56, 2005-2012.	6.7	155
81	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	5.6	151
82	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respiratory Research, 2017, 4, e000212.	3.0	151
83	CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society. Lancet Respiratory Medicine,the, 2015, 3, 483-496.	10.7	149
84	The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2020, 55, 2000085.	6.7	148
85	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 78-85.	5.6	147
86	Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients. BMC Pulmonary Medicine, 2019, 19, 16.	2.0	147
87	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	10.7	145
88	Imaging in Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 102-120.	2.1	143
89	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) â€" Report from OMERACT CTD-ILD Working Group. Journal of Rheumatology, 2015, 42, 2168-2171.	2.0	142
90	Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 767-776.	5.6	140

#	Article	IF	Citations
91	The Effect of Diffuse Pulmonary Fibrosis on the Reliability of CT Signs of Pulmonary Hypertension. Radiology, 2008, 249, 1042-1049.	7.3	139
92	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine,the, 2019, 7, 780-790.	10.7	139
93	Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 989-997.	5.6	138
94	Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases. Chest, 2020, 157, 1030-1042.	0.8	134
95	Increased Frequency of the Uncommon Tumor Necrosis Factor â^' 857T Allele in British and Dutch Patients with Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1119-1124.	5.6	133
96	The palliative care needs for fibrotic interstitial lung disease: A qualitative study of patients, informal caregivers and health professionals. Palliative Medicine, 2013, 27, 869-876.	3.1	131
97	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	6.7	129
98	Biopsy-proved Idiopathic Pulmonary Fibrosis: Spectrum of Nondiagnostic Thin-Section CT Diagnoses. Radiology, 2010, 254, 957-964.	7.3	128
99	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	10.7	128
100	Asbestosis and Idiopathic Pulmonary Fibrosis: Comparison of Thin-Section CT Features. Radiology, 2003, 229, 731-736.	7.3	124
101	Gastroesophageal Reflux Incites Interstitial Lung Disease in Systemic Sclerosis: Clinical, Radiologic, Histopathologic, and Treatment Evidence. Seminars in Arthritis and Rheumatism, 2010, 40, 241-249.	3.4	124
102	Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. European Radiology, 2011, 21, 1586-1593.	4.5	123
103	Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. European Respiratory Journal, 2012, 40, 641-648.	6.7	123
104	Sarcoidosis and Cancer Risk. Chest, 2015, 147, 778-791.	0.8	122
105	Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Human Molecular Genetics, 2010, 19, 4100-4111.	2.9	121
106	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials, 2017, 18, 275.	1.6	121
107	Predicting outcomes in rheumatoid arthritis related interstitial lung disease. European Respiratory Journal, 2019, 53, 1800869.	6.7	121
108	Acute Respiratory Distress Syndrome Caused by Pulmonary and Extrapulmonary Injury: A Comparative CT Study. Radiology, 2001, 218, 689-693.	7.3	118

#	Article	IF	Citations
109	Terminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias. American Journal of Clinical Pathology, 2003, 119, 709-714.	0.7	117
110	No pain relief from morphine?. Supportive Care in Cancer, 2006, 14, 56-64.	2.2	116
111	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 299-311.	5.6	110
112	Allergic Bronchopulmonary Aspergillosis in the Asthma Clinic. Chest, 2000, 118, 66-72.	0.8	108
113	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	10.7	108
114	Diagnosis and Evaluation of Hypersensitivity Pneumonitis. Chest, 2021, 160, e97-e156.	0.8	104
115	C-C Chemokine Receptor 2 and Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1162-1166.	5.6	103
116	An Essential Role for Resident Fibroblasts in Experimental Lung Fibrosis Is Defined by Lineage-Specific Deletion of High-Affinity Type II Transforming Growth Factor Î² Receptor. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 249-261.	5.6	103
117	Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis and Rheumatism, 2000, 43, 1633-1640.	6.7	102
118	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	5.6	102
119	Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention. Thorax, 2015, 70, 830-839.	5.6	97
120	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. European Respiratory Journal, 2015, 46, 1740-1750.	6.7	97
121	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 85-95.	10.7	96
122	Chronic Lung Disease in Adolescents With Delayed Diagnosis of Vertically Acquired HIV Infection. Clinical Infectious Diseases, 2012, 55, 145-152.	5.8	95
123	Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function. Chest, 2014, 145, 579-585.	0.8	95
124	Managing the supportive care needs of those affected by COVID-19. European Respiratory Journal, 2020, 55, 2000815.	6.7	95
125	Specialist Palliative Care is More Than Drugs: A Retrospective Study of ILD Patients. Lung, 2012, 190, 215-220.	3.3	94
126	Functional Impairment in Emphysema: Contribution of Airway Abnormalities and Distribution of Parenchymal Disease. American Journal of Roentgenology, 2005, 185, 1509-1515.	2.2	92

#	Article	IF	Citations
127	The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax, 2013, 68, 57-65.	5.6	92
128	BTS Clinical Statement on pulmonary sarcoidosis. Thorax, 2021, 76, 4-20.	5.6	90
129	Thin-Section CT in Obstructive Pulmonary Disease: Discriminatory Value. Radiology, 2002, 223, 812-819.	7.3	89
130	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosisâ€“associated interstitial lung disease trials. Arthritis Research and Therapy, 2015, 17, 372.	3.5	87
131	Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Current Opinion in Rheumatology, 2003, 15, 748-755.	4.3	86
132	Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax, 2013, 68, 867-879.	5.6	86
133	Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases. Chest, 2018, 153, 1416-1423.	0.8	85
134	Combined Pulmonary Fibrosis and Emphysema in SclerodermaâEŘelated Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension. Arthritis and Rheumatology, 2016, 68, 1004-1012.	5.6	84
135	Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications. Respiration, 2017, 93, 285-292.	2.6	82
136	Functional Consequences of Pleural Disease Evaluated with Chest Radiography and CT. Radiology, 2001, 220, 237-243.	7.3	75
137	Successful Treatment of Endogenous Lipoid Pneumonia due to Niemannâ€“Pick Type B Disease with Whole-Lung Lavage. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 128-131.	5.6	75
138	Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 491-498.	0.8	75
139	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	6.7	75
140	Covid-19 Interstitial Pneumonia: Histological and Immunohistochemical Features on Cryobiopsies. Respiration, 2021, 100, 488-498.	2.6	75
141	Palliative care for people with non-malignant lung disease: Summary of current evidence and future direction. Palliative Medicine, 2013, 27, 811-816.	3.1	74
142	The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respiratory Medicine,the, 2020, 8, 438-440.	10.7	74
143	Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax, 2012, 67, 938-940.	5.6	71
144	â€˜I wish I knew more ...â€™ the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals: TableÂ1. BMJ Supportive and Palliative Care, 2013, 3, 84-90.	1.6	71

#	Article	IF	Citations
145	Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1700379.	6.7	71
146	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	10.7	71
147	Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study. BMC Medicine, 2016, 14, 190.	5.5	69
148	Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1162-1171.	5.6	69
149	The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients. Respiration, 2018, 96, 338-347.	2.6	69
150	Challenges in pulmonary fibrosis {middle dot} 4: Smoking-induced diffuse interstitial lung diseases. Thorax, 2007, 62, 904-910.	5.6	68
151	Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. European Respiratory Journal, 2020, 55, 1901747.	6.7	67
152	Asymmetric ARDS Following Pulmonary Resection: CT Findingsâ€"Initial Observations. Radiology, 2002, 223, 468-473.	7.3	65
153	Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations. Radiology, 2017, 284, 255-263.	7.3	65
154	Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulmonary Medicine, 2018, 18, 177.	2.0	65
155	Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4Âin pulmonary fibrosis. Clinical Science, 2016, 130, 575-586.	4.3	64
156	C-C Chemokine Receptor 5 Gene Variants in Relation to Lung Disease in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 721-728.	5.6	62
157	Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores. European Radiology, 2018, 28, 1318-1327.	4.5	61
158	Major lung complications of systemic sclerosis. Nature Reviews Rheumatology, 2018, 14, 511-527.	8.0	60
159	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	5.6	60
160	Mycobacterium avium complex infection in nonâ€cystic fibrosis bronchiectasis. Respirology, 2014, 19, 714-722.	2.3	59
161	Morphine or Oxycodone for Cancer-Related Pain? A Randomized, Open-Label, Controlled Trial. Journal of Pain and Symptom Management, 2015, 49, 161-172.	1.2	59
162	Increased nitric oxide production in the respiratory tract in asymptomatic Pacific Islanders: An association with skin prick reactivity to house dust mite. Journal of Allergy and Clinical Immunology, 2000, 105, 895-899.	2.9	58

#	Article	IF	Citations
163	Pulmonary tumour thrombotic microangiopathy. Current Opinion in Pulmonary Medicine, 2016, 22, 421-428.	2.6	58
164	Unclassifiable interstitial lung diseases: Clinical characteristics and survival. Respirology, 2017, 22, 494-500.	2.3	58
165	Comorbidities in interstitial lung diseases. European Respiratory Review, 2017, 26, 160027.	7.1	57
166	Pleuroparenchymal Fibroelastosis. American Journal of Surgical Pathology, 2017, 41, 1683-1689.	3.7	57
167	Non-specific interstitial pneumonia in cigarette smokers: a CT study. European Radiology, 2009, 19, 1679-1685.	4.5	56
168	Smoking and interstitial lung diseases. European Respiratory Review, 2015, 24, 428-435.	7.1	56
169	Terminal Diffuse Alveolar Damage in Relation to Interstitial Pneumonias: An Autopsy Study. American Journal of Clinical Pathology, 2003, 119, 709-714.	0.7	56
170	Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax, 2013, 68, 309-310.	5.6	54
171	Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties. Radiology, 2021, 299, E216-E218.	7.3	54
172	Interstitial Lung Disease in Systemic Sclerosis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 213-221.	2.1	53
173	Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax, 2013, 68, 780-781.	5.6	52
174	Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis. BMC Pulmonary Medicine, 2017, 17, 81.	2.0	52
175	Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. Respiratory Medicine, 2018, 138, 95-101.	2.9	52
176	Variable utility of mosaic attenuation toÂdistinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1900531.	6.7	52
177	Fibroblastâ€specific perturbation of transforming growth factor Î² signaling provides insight into potential pathogenic mechanisms of sclerodermaâ€associated lung fibrosis: Exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis and Rheumatism, 2008, 58, 1175-1188.	6.7	51
178	Assessing Pulmonary Disease and Response to Therapy: Which Test?. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 409-418.	2.1	51
179	Smokingâ€related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung. Respirology, 2013, 18, 1191-1196.	2.3	51
180	Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. EBioMedicine, 2018, 28, 303-310.	6.1	51

#	Article	IF	Citations
181	Association between Heat Shock Protein 70/Hom Genetic Polymorphisms and Uveitis in Patients with Sarcoidosis. , 2007, 48, 3019.		50
182	Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Medicine, 2015, 13, 241.	5.5	50
183	Pulmonary Hypertension in Patients With Bronchiectasis: Prognostic Significance of CT Signs. American Journal of Roentgenology, 2011, 196, 1300-1304.	2.2	49
184	Interstitial lung disease in systemic sclerosis. Presse Medicale, 2014, 43, e329-e343.	1.9	48
185	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	6.7	48
186	Cryptogenic Organizing Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 449-460.	2.1	47
187	Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. Respirology, 2014, 19, 138-143.	2.3	47
188	Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis. Respiratory Research, 2017, 18, 218.	3.6	47
189	Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. Lancet Respiratory Medicine,the, 2020, 8, 1144-1153.	10.7	47
190	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. European Respiratory Journal, 2021, 58, 2004188.	6.7	47
191	Quantification of emphysema: a composite physiologic index derived from CT estimation of disease extent. European Radiology, 2007, 17, 911-918.	4.5	46
192	Bronchiectasis: A neglected cause of respiratory morbidity and mortality. Respirology, 1996, 1, 221-225.	2.3	45
193	Interstitial Lung Disease: Effects of Thin-Section CT on Clinical Decision Making. Radiology, 2006, 238, 725-733.	7.3	45
194	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	5.6	45
195	Nitrofurantoin-Induced Lung Disease: Two Cases Demonstrating Resolution of Apparently Irreversible CT Abnormalities. Journal of Computer Assisted Tomography, 2000, 24, 259-261.	0.9	45
196	Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia. Clinics in Chest Medicine, 2004, 25, 717-726.	2.1	44
197	Managing diagnostic procedures in idiopathic pulmonary fibrosis. European Respiratory Review, 2013, 22, 158-162.	7.1	44
198	Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices. Respiratory Medicine, 2017, 130, 43-51.	2.9	44

#	Article	IF	Citations
199	Computed Tomographic Imaging in Connective Tissue Diseases. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 389-397.	2.1	43
200	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Respiration, 2013, 86, 265-274.	2.6	43
201	Effect of Aging on Lung Structure In Vivo. Journal of Thoracic Imaging, 2012, 27, 366-371.	1.5	42
202	Imaging aspects of the diagnosis of sarcoidosis. European Radiology, 2014, 24, 807-816.	4.5	42
203	Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. European Respiratory Journal, 2020, 55, 1901519.	6.7	42
204	Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial. European Respiratory Journal, 2020, 56, 1901520.	6.7	41
205	Proteomic Analysis of Kveim Reagent Identifies Targets of Cellular Immunity in Sarcoidosis. PLoS ONE, 2017, 12, e0170285.	2.5	41
206	The frequency of neuroendocrine cell hyperplasia in patients with pulmonary neuroendocrine tumours and nonâ€neuroendocrine cell carcinomas. Histopathology, 2009, 55, 332-337.	2.9	40
207	Advanced sarcoidosis. Current Opinion in Pulmonary Medicine, 2019, 25, 497-504.	2.6	40
208	Rare idiopathic interstitial pneumonias: <scp>LIP</scp> and <scp>PPFE</scp> and rare histologic patterns of interstitial pneumonias: <scp>AFOP</scp> and <scp>BPIP</scp>. Respirology, 2016, 21, 600-614.	2.3	39
209	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology, 2018, 23, 687-694.	2.3	39
210	Normal Adult Values, Diurnal Variation, and Repeatability of Nasal Nitric Oxide Measurement. American Journal of Rhinology & Allergy, 1999, 13, 401-406.	2.2	38
211	Nonspecific Interstitial Pneumoniaâ€"Nobody Said It's Perfect. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1553-1554.	5.6	38
212	Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis: Quantitative High Resolution Computed Tomography of the Chest Scoring. Journal of Rheumatology, 2009, 36, 1460-1463.	2.0	38
213	The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology, 2010, 15, 1226-1232.	2.3	38
214	Accuracy of Individual Variables in the Monitoring of Long-term Change in Pulmonary Sarcoidosis as Judged by Serial High-Resolution CT Scan Data. Chest, 2014, 145, 101-107.	0.8	38
215	Pulmonary tumour thrombotic microangiopathy: unclassifiable pulmonary hypertension?. European Respiratory Journal, 2015, 46, 1214-1217.	6.7	38
216	Mucins MUC5B and MUC5AC in Distal Airways and Honeycomb Spaces: Comparison among Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia, Fibrotic Nonspecific Interstitial Pneumonitis, and Control Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 462-464.	5.6	38

#	Article	IF	Citations
217	Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study. Lancet Respiratory Medicine,the, 2020, 8, 786-794.	10.7	38
218	Respiratory Bronchiolitis-Associated Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 585-594.	2.1	37
219	Histopathologic Diagnosis in Diffuse Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 828-829.	5.6	37
220	Pulmonary Complications of Connective Tissue Diseases. Clinics in Chest Medicine, 2008, 29, 149-164.	2.1	37
221	Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis and Rheumatism, 2011, 63, 3531-3539.	6.7	37
222	Elevated Pulmonary Arterial Systolic Pressure in Patients with Sarcoidosis: Prevalence and Risk Factors. Lung, 2013, 191, 61-67.	3.3	37
223	A Comparison of Methods for Enhancing the Detection of Areas of Decreased Attenuation on CT Caused by Airways Disease. Journal of Computer Assisted Tomography, 1999, 23, 385-389.	0.9	37
224	Smoking-related idiopathic interstitial pneumonia. European Respiratory Journal, 2014, 44, 594-602.	6.7	36
225	When the Game Changes. Chest, 2020, 158, 892-895.	0.8	36
226	A Biomarker Panel (Bioscore) Incorporating Monocytic Surface and Soluble TREM-1 Has High Discriminative Value for Ventilator-Associated Pneumonia: A Prospective Observational Study. PLoS ONE, 2014, 9, e109686.	2.5	36
227	Asbestos-induced and Smoking-related Disease: Apportioning Pulmonary Function Deficit by Using Thin-Section CT. Radiology, 2007, 242, 258-266.	7.3	35
228	â€œAny fool can make a rule and any fool will mind itâ€• BMC Medicine, 2016, 14, 23.	5.5	35
229	Visual and Automated CT Measurements of Lung Volume Loss in Idiopathic Pulmonary Fibrosis. American Journal of Roentgenology, 2019, 213, 318-324.	2.2	35
230	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	2.9	34
231	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. European Respiratory Journal, 2020, 56, 1902135.	6.7	34
232	Loss of FEV1 in cystic fibrosis: correlation with HRCT features. European Radiology, 2002, 12, 2229-2235.	4.5	33
233	Traction bronchiectasis in cryptogenic fibrosing alveolitis: associated computed tomographic features and physiological significance. European Radiology, 2003, 13, 1801-1808.	4.5	33
234	Pulmonary Function Tests in Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 379-388.	2.1	33

#	Article	IF	Citations
235	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.8	33
236	The need to research refractory breathlessness. European Respiratory Journal, 2016, 47, 342-343.	6.7	32
237	Variable radiological lung nodule evaluation leads to divergent management recommendations. European Respiratory Journal, 2018, 52, 1801359.	6.7	32
238	Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. Chest, 2019, 155, 972-981.	0.8	32
239	The potential impact of azithromycin in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800628.	6.7	32
240	Diffuse Cystic Lung Disease of Unexplained Cause With Coexistent Small Airway Disease. American Journal of Surgical Pathology, 2012, 36, 228-234.	3.7	31
241	Morphometric analysis of intralobular, interlobular and pleural lymphatics in normal human lung. Journal of Anatomy, 2012, 220, 396-404.	1.5	31
242	Sarcoidosis and Tuberculosis Cytokine Profiles: Indistinguishable in Bronchoalveolar Lavage but Different in Blood. PLoS ONE, 2012, 7, e38083.	2.5	31
243	Pulmonary function, CT and echocardiographic abnormalities in sickle cell disease. Thorax, 2014, 69, 746-751.	5.6	31
244	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Review of Clinical Pharmacology, 2017, 10, 483-491.	3.1	31
245	Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respiratory Research, 2019, 20, 47.	3.6	31
246	Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 82-90.	0.2	31
247	The Kingâ€™s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respiratory Research, 2019, 6, e000363.	3.0	30
248	Right Ventricular to Left Ventricular Ratio atÂCT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease. Chest, 2020, 157, 89-98.	0.8	30
249	Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax, 2020, 75, 407-412.	5.6	30
250	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	2.3	30
251	Mechanism of mosaic attenuation of the lungs on computed tomography in induced bronchospasm. Journal of Applied Physiology, 1999, 86, 701-708.	2.5	29
252	Prostacyclin for pulmonary hypertension in adults. The Cochrane Library, 2005, , CD002994.	2.8	29

#	Article	IF	Citations
253	Daily Cyclophosphamide for Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 952-953.	5.6	29
254	Bronchiectasis in yellow nail syndrome. Respirology, 2017, 22, 101-107.	2.3	29
255	Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23, 593-599.	2.3	29
256	Deep Learningâ€“based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 883-891.	5.6	29
257	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Current Rheumatology Reviews, 2010, 6, 138-144.	0.8	28
258	Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax, 2014, 69, 287-288.	5.6	28
259	The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease. Journal of Palliative Medicine, 2016, 19, 549-555.	1.1	28
260	Mixed Ventilatory Defects in Pulmonary Sarcoidosis. Chest, 2020, 158, 2007-2014.	0.8	28
261	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. European Respiratory Review, 2022, 31, 210165.	7.1	28
262	Evaluation of Patients Undergoing Lung Volume Reduction Surgery: Ancillary Information Available from Computed Tomography. Clinical Radiology, 2000, 55, 45-50.	1.1	27
263	Severe Sarcoidosis. Clinics in Chest Medicine, 2015, 36, 715-726.	2.1	27
264	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study â€“ Rationale and study design. Respiratory Medicine, 2018, 138, 13-20.	2.9	27
265	Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging pattern. European Respiratory Journal, 2019, 54, 1901144.	6.7	27
266	Patient-specific bronchoscopy visualization through BRDF estimation and disocclusion correction. IEEE Transactions on Medical Imaging, 2006, 25, 503-513.	8.9	26
267	Pulmonary vascular limitation to exercise and survival in idiopathic pulmonary fibrosis. Respirology, 2014, 19, 269-275.	2.3	26
268	Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today, 2015, 20, 514-524.	6.4	26
269	Brief Report: Antiâ€“Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 2778-2783.	5.6	26
270	Subclinical Interstitial Lung Abnormalities: Toward the Early Detection of Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1445-1446.	5.6	26

#	Article	IF	Citations
271	Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax, 2020, 75, 648-654.	5.6	26
272	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.8	26
273	Evaluation of visual and computer-based CT analysis for the identification of functional patterns of obstruction and restriction in hypersensitivity pneumonitis. Respirology, 2017, 22, 1585-1591.	2.3	25
274	Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 184-193.	2.1	25
275	Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category?: Table 1â€“. European Respiratory Journal, 2013, 42, 576-579.	6.7	24
276	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	2.6	24
277	Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 155, 712-719.	0.8	24
278	COVIDâ€19 related lung pathology: old patterns in new clothing?. Histopathology, 2020, 77, 169-172.	2.9	24
279	Lung fibrosis: new classifications and therapy. Current Opinion in Rheumatology, 2001, 13, 500-504.	4.3	23
280	Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology, 2012, 17, 674-680.	2.3	23
281	The evolving pharmacotherapy of pulmonary fibrosis. Expert Opinion on Pharmacotherapy, 2013, 14, 79-89.	1.8	23
282	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology, 2017, 56, v27-v32.	1.9	23
283	Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation. BioMed Research International, 2019, 2019, 1-11.	1.9	23
284	Nasal Levels of Nitric Oxide as an Outcome Variable in Allergic Upper Respiratory Tract Disease: Influence of Atopy and Hayfever on nNO. American Journal of Rhinology & Allergy, 2006, 20, 425-429.	2.2	22
285	Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. European Respiratory Journal, 2019, 54, 1802341.	6.7	22
286	Risk factors for disease progression in idiopathic pulmonary fibrosis. Thorax, 2020, 75, 78-80.	5.6	22
287	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	2.6	22
288	MiR-185/AKT and miR-29a/Collagen 1a pathways are activated in IPF BAL cells. Oncotarget, 2016, 7, 74569-74581.	1.8	22

#	Article	IF	Citations
289	CT Evaluation of Fibrosing Alveolitisâ€"Applications and Insights. Journal of Thoracic Imaging, 1996, 11, 231-249.	1.5	21
290	High-Resolution Computed Tomography in the Diagnosis of Diffuse Lung Disease: A Clinical Perspective. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 347-356.	2.1	21
291	Update in Diffuse Parenchymal Lung Disease 2006. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 655-660.	5.6	21
292	Clinical Relevance of Plasma Prostaglandin F2Î± Metabolite Concentrations in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2013, 8, e66017.	2.5	21
293	Fibrotic idiopathic interstitial pneumonias: Mortality is linked to a decline in gas transfer. Respirology, 2010, 15, 1233-1243.	2.3	20
294	Medical Therapy in Idiopathic Pulmonary Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 368-377.	2.1	20
295	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	6.7	20
296	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation, 2021, 40, 494-503.	0.6	20
297	Treatment strategies for idiopathic interstitial pneumonias. Current Opinion in Pulmonary Medicine, 2014, 20, 442-448.	2.6	19
298	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.8	19
299	Monitoring of Lung Involvement in Rheumatologic Disease. Respiration, 2016, 91, 89-98.	2.6	18
300	PET scanning of macrophages in patients with scleroderma fibrosing alveolitis. Nuclear Medicine and Biology, 2008, 35, 901-909.	0.6	17
301	New pharmacological strategies for the treatment of pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2010, 4, 353-366.	2.6	17
302	Interstitial pneumonitis with autoimmune features (IPAF): a work in progress. European Respiratory Journal, 2016, 47, 1622-1624.	6.7	17
303	Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. Trials, 2017, 18, 201.	1.6	17
304	Quantitative CTâ€derived vessel metrics in idiopathic pulmonary fibrosis: A structureâ€"function study. Respirology, 2019, 24, 445-452.	2.3	17
305	Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. Frontiers in Immunology, 2021, 12, 645548.	4.8	17
306	Update in Diffuse Parenchymal Lung Disease 2007. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 580-584.	5.6	16

#	Article	IF	Citations
307	Prognostic factors in rapidly progressive interstitial pneumonia. Respirology, 2010, 15, 257-264.	2.3	16
308	A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Research, 2018, 4, 00124-2017.	2.6	16
309	Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert Opinion on Pharmacotherapy, 2021, 22, 191-204.	1.8	16
310	Interstitial pneumonia with autoimmune features: challenges and controversies. European Respiratory Review, 2021, 30, 210177.	7.1	16
311	Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients. Pulmonary Pharmacology and Therapeutics, 2008, 21, 840-844.	2.6	15
312	Method for Minimizing Observer Variation for the Quantitation of High-Resolution Computed Tomographic Signs of Lung Disease. Journal of Computer Assisted Tomography, 2011, 35, 596-601.	0.9	15
313	Early diagnosis of IPF: time for a primary-care case-finding initiative?. Lancet Respiratory Medicine,the, 2014, 2, e1.	10.7	15
314	Psychometric validation of the needs assessment tool: progressive disease in interstitial lung disease. Thorax, 2018, 73, 880-883.	5.6	15
315	Sarcoidosis: A benign disease or a culture of neglect?. Respiratory Medicine, 2018, 144, S1-S2.	2.9	15
316	BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 136-139.	5.6	15
317	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	2.3	15
318	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	5.6	15
319	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine, 2022, 196, 106801.	2.9	15
320	Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives. European Respiratory Review, 2022, 31, 210206.	7.1	15
321	Interlobular Septal Thickening in Idiopathic Bronchiectasis: A Thin-Section CT Study of 94 Patients. Radiology, 2005, 237, 1091-1096.	7.3	14
322	Alveolar proteinosis with hypersensitivity pneumonitis: A new clinical phenotype. Respirology, 2010, 15, 1197-1202.	2.3	14
323	Pamrevlumab in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2020, 8, 2-3.	10.7	14
324	New insights into the treatment of CTD-ILD. Nature Reviews Rheumatology, 2021, 17, 79-80.	8.0	14

#	Article	IF	Citations
325	Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110596.	2.7	14
326	CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1440-1448.	5.6	14
327	Lost in translation; from animal models of pulmonary fibrosis to human disease. Respirology, 2009, 14, 915-916.	2.3	13
328	Cultural Differences in Palliative Care in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, e56.	0.8	13
329	Advances in imaging of cardiopulmonary involvement in sarcoidosis. Current Opinion in Pulmonary Medicine, 2015, 21, 538-545.	2.6	13
330	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	3.4	13
331	POINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? Yes. Chest, 2017, 152, 917-919.	0.8	13
332	Validation of multidisciplinary diagnosis in IPF. Lancet Respiratory Medicine,the, 2018, 6, 88-89.	10.7	13
333	Communication difficulties reported by patients diagnosed with idiopathic pulmonary fibrosis and their carers: a European focus group study. ERJ Open Research, 2019, 5, 00055-2019.	2.6	13
334	The role of precision medicine in interstitial lung disease. European Respiratory Journal, 2022, 60, 2102146.	6.7	13
335	Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Research, 2022, 8, 00115-2022.	2.6	13
336	Computed tomographic imaging of bronchiolar disorders. Current Opinion in Pulmonary Medicine, 1998, 4, 85-92.	2.6	12
337	Spirometric lung volumes in the adult Pacific Islander population: Comparison with predicted values in a European population. Respirology, 2001, 6, 247-253.	2.3	12
338	Road ahead to respiratory health: Experts chart future research directions. Respirology, 2009, 14, 625-636.	2.3	12
339	Non-invasive assessment of pulmonary blood flow using an inert gas rebreathing device in fibrotic lung disease. Thorax, 2010, 65, 341-345.	5.6	12
340	IPF diagnosis: flexibility is a virtue. Lancet Respiratory Medicine,the, 2018, 6, 735-737.	10.7	12
341	Diagnosing complications and co-morbidities of fibrotic interstitial lung disease. Expert Review of Respiratory Medicine, 2019, 13, 645-658.	2.5	12
342	Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clinical Rheumatology, 2020, 39, 1173-1179.	2.2	12

#	Article	IF	Citations
343	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosisâ€“associated Interstitial Lung Disease. Journal of Rheumatology, 2021, 48, 1295-1298.	2.0	12
344	Peripheral-type benzodiazepine receptors in bronchoalveolar lavage cells of patients with interstitial lung disease. Nuclear Medicine and Biology, 2007, 34, 553-558.	0.6	11
345	Azithromycin in bronchiectasis: when should it be used?. Lancet, The, 2012, 380, 627-629.	13.7	11
346	Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard. European Respiratory Journal, 2015, 45, 1208-1210.	6.7	11
347	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. European Respiratory Journal, 2020, 55, 1901681.	6.7	11
348	Shortâ€term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis. Respirology, 2022, 27, 202-208.	2.3	11
349	Diffuse alveolar damage in idiopathic pulmonary fibrosis: Does aetiology matter?. Respirology, 2010, 15, 873-875.	2.3	10
350	The Prognostic Value of the GAP Model In Chronic Interstitial Lung Disease. Chest, 2014, 145, 672-674.	0.8	10
351	Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. Journal of Clinical Epidemiology, 2015, 68, 1019-1027.	5.0	10
352	Why do people die from pulmonary sarcoidosis?. Current Opinion in Pulmonary Medicine, 2018, 24, 527-535.	2.6	10
353	Before Freezing Out Cryobiopsy, We Need to Thaw Out Flaws in the Diagnosis of Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 937-938.	5.6	10
354	Transbronchial Cryobiopsy in Interstitial Lung Diseases. Journal of Bronchology and Interventional Pulmonology, 2021, 28, 81-92.	1.4	10
355	The Art and Science of Diagnosing Interstitial Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 974-975.	5.6	9
356	Evidence-based Recommendations in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 5-7.	5.6	9
357	Idiopathic Pulmonary Fibrosis Pathogenesis and Novel Approaches to Immunomodulation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 677-679.	5.6	9
358	New Treatments for Idiopathic Pulmonary Fibrosis: â€˜Die Another Day' if Diagnosed Early?. Respiration, 2015, 90, 352-352.	2.6	9
359	Nonspecific interstitial pneumonia. Current Opinion in Pulmonary Medicine, 2016, 22, 450-455.	2.6	9
360	Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 112-113.	5.6	9

#	Article	IF	Citations
361	A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression?. European Respiratory Journal, 2021, 57, 2004354.	6.7	9
362	Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). Respiratory Medicine, 2022, 191, 106436.	2.9	9
363	Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases. Annals of the American Thoracic Society, 2022, 19, 737-745.	3.2	9
364	Accurate diagnosis of cardiac sarcoidosis needs a multidisciplinary approach. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 614-615.	0.5	8
365	Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. Respiratory Medicine, 2016, 120, 131-133.	2.9	8
366	Idiopathic pulmonary fibrosis: idiopathic no more?. Lancet Respiratory Medicine,the, 2018, 6, 84-85.	10.7	8
367	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. Expert Review of Clinical Immunology, 2018, 14, 127-135.	3.0	8
368	Treatment of cardiac sarcoidosis. Current Opinion in Pulmonary Medicine, 2019, 25, 519-525.	2.6	8
369	Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?. Thorax, 2020, 75, 901-903.	5.6	8
370	Residual Lung Disease at Six-month Follow-up CT after COVID-19: Clinical Significance Is a Key Issue. Radiology, 2021, 301, E406-E408.	7.3	8
371	A Combined Pulmonary Function and Emphysema Score Prognostic Index for Staging in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e111109.	2.5	8
372	Classification of Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 141-142.	5.6	7
373	Update in Interstitial Lung Disease 2016. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 132-138.	5.6	7
374	Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial. European Respiratory Journal, 2020, 55, 1901157.	6.7	7
375	Lung Parenchymal and Tracheal CT Morphology: Evaluation before and after Bariatric Surgery. Radiology, 2020, 294, 669-675.	7.3	7
376	Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study. BMJ Open, 2021, 11, e048808.	1.9	7
377	The progressive fibrotic phenotype in current clinical practice. Current Opinion in Pulmonary Medicine, 2021, 27, 368-373.	2.6	7
378	Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32 Suppl 1, 28-35.	0.2	7

#	Article	IF	Citations
379	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. European Respiratory Journal, 2017, 49, 1602524.	6.7	6
380	Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what'sÂin a name?. European Respiratory Journal, 2019, 53, 1801939.	6.7	6
381	Pulmonary vascular involvement in <scp>COVID</scp>â€19 pneumonitis: Is this the first and final insult?. Respirology, 2021, 26, 832-834.	2.3	6
382	Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema. ERJ Open Research, 2021, 7, 00316-2021.	2.6	6
383	Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine, 2021, 38, 101009.	7.1	6
384	Diagnostic approach to interstitial lung disease. Current Respiratory Care Reports, 2012, 1, 199-207.	0.6	5
385	A rapidly growing lung mass with air crescent formation. Thorax, 2013, 68, 394-395.	5.6	5
386	Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy. Multidisciplinary Respiratory Medicine, 2019, 14, 3.	1.5	5
387	Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed. Lancet Respiratory Medicine,the, 2021, 9, 437-438.	10.7	5
388	Inhaled trepostinil for severe fibrotic interstitial lung disease: grounds for cautious optimism?. Lancet Respiratory Medicine,the, 2021, 9, 1209-1211.	10.7	5
389	Chronic hypersensitivity pneumonitis in the setting of definite IPF: does the current study undermine IPF guideline recommendations?. Lancet Respiratory Medicine,the, 2013, 1, 664-665.	10.7	4
390	Morphologic Predictors of a Microbiological Yield in Patients With a Tree-in-Bud Pattern on Computed Tomography. Journal of Thoracic Imaging, 2014, 29, 240-245.	1.5	4
391	An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?. Expert Review of Clinical Immunology, 2021, 17, 1091-1101.	3.0	4
392	Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis. ERJ Open Research, 2021, 7, 00107-2020.	2.6	4
393	If it was good enough for Aristotle..... Thorax, 2011, 66, 183-1184.	5.6	3
394	Pulmonary capillary haemangiomatosis â€“ An unusual cause of hypoxia. Respiratory Medicine Case Reports, 2012, 7, 12-14.	0.4	3
395	Tobacco industry lobbyists and their health-care clients. Lancet, The, 2013, 381, 445.	13.7	3
396	Idiopathic interstitial pneumonias in 2015: A new era. Respirology, 2015, 20, 697-698.	2.3	3

#	Article	IF	Citations
397	Sarcoidosis of the cardioâ€“pulmonary systems. Clinical Medicine, 2016, 16, 34-41.	1.9	3
398	Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail. Respirology, 2018, 23, 244-245.	2.3	3
399	Sarcoidosis: is cryobiopsy not cool enough? â€“ Authors' reply. Lancet Respiratory Medicine,the, 2018, 6, e45.	10.7	3
400	Early histological changes of pulmonary arterial hypertension disclosed by invasive cardiopulmonary exercise testing. Pulmonary Circulation, 2019, 9, 1-4.	1.7	3
401	Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution. Lancet Respiratory Medicine,the, 2019, 7, 7-8.	10.7	3
402	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, , .	3.4	3
403	Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis and Rheumatism, 2000, 43, 1633.	6.7	3
404	Idiopathic pulmonary fibrosisâ€related pulmonary hypertension; an exercising diagnosis?. Respirology, 2011, 16, 381-383.	2.3	2
405	Baseline Values and Short Serial Change. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 395-397.	5.6	2
406	Image Quality of Computed Tomographic Pulmonary Angiography for Suspected Pulmonary Embolus in Patients With Diffuse Interstitial Lung Disease. Journal of Thoracic Imaging, 2012, 27, 156-163.	1.5	2
407	Recurrent pneumothoraces in a 17-year-old man with mixed connective tissue disease. Thorax, 2014, 69, 685-686.	5.6	2
408	Pulmonary Vasospasm in Systemic Sclerosis: Noninvasive Techniques for Detection. Pulmonary Circulation, 2015, 5, 498-505.	1.7	2
409	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still openâ€”Authors' reply. Lancet Respiratory Medicine,the, 2017, 5, e3.	10.7	2
410	Rapidly Progressive Cystic Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 264-264.	5.6	2
411	Novel exploratory data in interstitial lung disease. Respirology, 2019, 24, 718-719.	2.3	2
412	Pulmonary Complications of Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 145-146.	2.1	2
413	Contemporary Concise Review 2019: Interstitial lung disease. Respirology, 2020, 25, 756-763.	2.3	2
414	Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?. European Respiratory Journal, 2020, 55, 2000590.	6.7	2

#	Article	IF	Citations
415	Non-Langerhans Histiocytosis Mimicking Sarcoidosis on High-resolution Computed Tomography. Journal of Thoracic Imaging, 2010, 25, W133-W135.	1.5	2
416	Year in review 2009: Interstitial lung diseases, acute injury, sleep, physiology, imaging and bronchoscopic intervention. Respirology, 2010, 15, 172-181.	2.3	1
417	CT Detection of Pulmonary Hypertension in Interstitial Lung Disease: The Glass Is Half Full. Radiology, 2011, 260, 628-631.	7.3	1
418	Pirfenidone and N-acetylcysteine (NAC) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF): Exploratory Efficacy Results From the PANORAMA Study. Chest, 2015, 148, 641A.	0.8	1
419	Predicting time to decline in FVC using baseline visual and computer-based CT analysis and baseline functional indices. Clinical Radiology, 2017, 72, S24.	1.1	1
420	A new era in idiopathic interstitial pneumonias: <scp>E</scp>pilogue to a review series. Respirology, 2017, 22, 14-16.	2.3	1
421	Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny path. Respirology, 2019, 24, 620-621.	2.3	1
422	Pulmonary fibrosis: â€œidiopathicâ€•is not â€œcryptogenicâ€• European Respiratory Journal, 2019, 53, 1900400.	6.7	1
423	Drug treatments of the future in fibrotic lung disease. , 2003, , 336-360.		0
424	Pulmonary Complications of Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 367-368.	2.1	0
425	Elevated Pulmonary Arterial Systolic Pressure (PASP) in Patients With Sarcoidosis: Prevalence and Risk Factors. Chest, 2014, 145, 244A.	0.8	0
426	Increased Spatial QRS-T Angle in First-Diagnosed Sarcoidosis Patients as a Marker of Cardiac Involvement. Chest, 2014, 145, 86A.	0.8	0
427	BNP Can Be an All-Cause Mortality Predictor in Sarcoidosis. Chest, 2014, 145, 253A.	0.8	0
428	Management of Scleroderma-Associated Pulmonary Involvement. Current Treatment Options in Rheumatology, 2015, 1, 51-67.	1.4	0
429	P065 <break /> A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	0
430	Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of Composite Physiologic Index at Baseline in the INPULSIS Trials. Chest, 2016, 150, 539A.	0.8	0
431	Computer based CT scoring versus visual CT scores: identifying optimal predictors of functional decline and mortality in IPF. Clinical Radiology, 2016, 71, S26.	1.1	0
432	Rebuttal From Drs Wells andÂKokosi. Chest, 2017, 152, 922-923.	0.8	0

#	Article	IF	Citations
433	A rigid solution to a relapsing problem. Lancet Respiratory Medicine,the, 2017, 5, 760.	10.7	0
434	The Genomic Detection of Usual Interstitial Pneumonia from Transbronchial Biopsy Tissue: A Dress Rehearsal for the Future?. Annals of the American Thoracic Society, 2017, 14, 1632-1633.	3.2	0
435	Regarding the â€œEvaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statementâ€• Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 182-183.	0.5	0
436	Mortality in Sarcoidosis. , 2019, , 305-312.		0
437	Interstitial lung diseases: courseÂreport. Breathe, 2019, 15, 270-272.	1.3	0
438	Patients with idiopathic pulmonary fibrosis: Overcoming â€˜geographic isolationâ€™. Respirology, 2020, 25, 1019-1020.	2.3	0
439	Reply to Althuwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 522-524.	5.6	0
440	P157â€ƒPotential benefit of intravenous immunoglobulin in connective tissue disease associated interstitial lung diseases. Rheumatology, 2021, 60, .	1.9	0
441	General Principles of ILD: Diagnosis and Management. , 2022, , 1-9.		0
442	Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).. Blood, 2004, 104, 1831-1831.	1.4	0
443	Lung Function and High Resolution Computed Tomography in Sickle Cell Disease.. Blood, 2005, 106, 3182-3182.	1.4	0
444	REPRODUCIBILITY OF RELATIVE REGIONAL ASSESSMENT USING THE VIBRATION RESPONSE IMAGING DEVICE. Chest, 2006, 130, 169S.	0.8	0
445	World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021051.	0.2	0
446	Interstitial Lung Abnormalities: An Evolving Entity. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
447	Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management. Annals of the American Thoracic Society, 2022, 19, 904-906.	3.2	0